Jaime Merchan, MD, discusses the background and findings from the LITESPARK-013 trial of belzutifan for the treatment of patients with advanced clear cell renal cell carcinoma.
Jaime Merchan, MD, professor, co-leader of the Translational and Clinical Oncology Research Program and director of the phase 1 clinical trials program at the Sylvester Comprehensive Cancer Center at the University of Miami, discusses the background and findings from the LITESPARK-013 trial (NCT04489771) which evaluated belzutifan (Welireg), a hypoxia-inducible factor (HIF)–2α inhibitor, in patients with advanced clear cell renal cell carcinoma.
Transcription:
0:09 | LITESPARK-013 was a randomized, phase 2 trial comparing 2 different dose levels of belzutifan, a novel HIF–2α blocker in patients with clear cell renal cell carcinoma. The objectives of the study were to try to determine the differences in the efficacy between the 2 doses, the standard dose of 120 mg per day vs the high dose of 200 mg per day.
0:39 | The results of the study presented last year at [the 2023 European Society of Medical Oncology Annual Meeting] showed that both the low and the high doses of belzutifan were associated with similar efficacy with similar response rates and also no significant differences in a median progression-free survival, suggesting that both doses were effective and probably that the lower dose of 120 [mg], which is the standard dose, is enough to induce clinical benefit.
1:14 | The current study, [that was] presented at [the American Society of Clinical Oncology] 2024 [Annual Meeting], is a post hoc efficacy analysis conducted on a pooled population. The analysis included both low- and high-dose treated patients to explore potential correlations between efficacy and various clinical factors. These factors included differences in IMBC scores, differentiation status, the number of prior lines of therapy (one or more), and the type of first-line therapy administered, such as [tyrosine kinase inhibitors] or checkpoint inhibitors.
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen